Apogee Therapeutics’ Post

Successful deals start with trust. At LSI USA ‘23, Chris Eso having led multiple key deals at Medtronic shared two important components in the recipe for a successful acquisition: Identifying a strong strategic fit, and meeting financial expectations for both shareholders and investors. Having great technology in a great market is table stakes. In a landscape where you’re often vying for a deal against others in a competitive market, there needs to be clear alignment on fit and financials to tip the scales in your favor. As Chris says, nothing is ever completely “one sided” — you have to “feel a little pain and give a little pain” which is made much more palatable when you have that clear alignment on fit and financials. Learn more by watching the full panel, The Anatomy of a Medtech Deal, here: https://lnkd.in/e_qmNW8b

Best Performing U.S. IPOs of 2023 🚀 Jin Medical International topped the 2023 U.S. IPO performance chart with a staggering 3000% return despite facing delisting risks. The healthcare sector, particularly companies like RayzeBio and Structure Therapeutics, dominated the list of top IPOs, showcasing significant investor interest in health-related innovations. Alongside healthcare's strong showing, technology firms like Alpha Technology Group and ICZOOM Group, financial services, the food & beverage sector represented by CAVA Group, and the energy sector via Nextracker also made notable appearances among the top IPOs, indicating a broad range of interests from investors. With 154 IPOs in 2023, there was a noticeable decrease from previous years, highlighting a more cautious IPO market amid various economic pressures. #investing #stocks #wealth #IPOs #markets Source - Visual Capitalist *** If you enjoyed reading this or learned something, ♻️ share this with others and 🔔 follow me Taras Rybak for more.

Augmedix, Inc. (Nasdaq: $AUGX) announced the closing of a registered public offering of common stock for aggregate gross proceeds of $28.75 million. Read more: https://lnkd.in/diqANM55 #microcaps #nasdaq #commonstock #investing #finance #businessupdate

Only one week left to register! Join our webinar on March 21 with Don Stockslager, Head of Business Systems at Revalize, for a discussion on seamless acquisition integrations. Explore how Revalize harnessed the power of Spaulding Ridge and Salesforce to standardize processes across departments, unify systems for scalable operations, and conduct a major cleanup of data structures, modernizing operations for efficiency and agility. Register today and don't miss out: https://bit.ly/42V6hC2 #SpauldingRidge #Revalize #MergersAndAcquisitions

Excited for another day at the NYSE immersing in IPO intricacies and financial strategies from CFOs, followed by an insightful discussion with CAVA CEO and NYSE President. Afternoon with investment bankers discussing trends in the spine industry, and growth opportunities in #motionpreservation and less invasive #outpatientsurgery. Grateful for valuable connections and insights. Emphasizing the importance of your network and the right team for a successful IPO journey. 🙏 #healthcareinvestment #iporeadiness #IPOSummit #growthstrategies #cfoinsights Connor Group AxioMed NANISX

Consider investing in May 2024: FirstCash( $FCFS ), Visa( $V ), Alphabet( $GOOG ), International Game( $IGT ), First Citizens( $FCNCA ), Accenture Plc( $ACN ), Torm PLC( $TRMD ), Nu Holdings( $NU ), Astria Therapeutics( $ATXS ), AGNC Investment( $AGNC ), Western Union( $WU ) and Alphabet( $GOOG ) https://lnkd.in/gSga9XDX #stocks #stocktwits #thematic_portfolio

Astera Labs IPO: Our view & details. Astera Labs (Nasdaq Ticker: ALAB) – the AI stock saw strong buying action during its IPO trading and even follow through this morning pushing its share price as high as $80 after pricing its IPO at $36. Here we analyze the future of Astera Labs after its IPO. The first trade for ALAB was $52 and this one was a little bit below the radar screen. The big idea here is that we haven’t had this much IPO activity in quite a while. The IPO deal for Astera Labs was priced very strong and had very good market reception. That is a very bullish indicator. The caveat here is what happened in ALAB at the end of the trading day. The stock was up as much as 25% during the first trading hours before turning around and heading back down to $64 a share and posting a gain of only 3.5%. Profit taking in that stock is more than acceptable with it up more than 100% from the offering price and 60% up from the first trade. Offering Details: The IPO consists of a total of 17.8 million shares. Approximately 14.79 million shares are offered by the company itself. Roughly 3.01 million shares are being sold by existing stockholders. The stock was expected to be priced between $27.00 and $30.00 per share. In fact the IPO price increased to $36 per share. The shares are trading on the Nasdaq Global Select Market under the ticker symbol “ALAB“. Underwriters: Morgan Stanley and J.P. Morgan were acting as joint book runners for the offering. Other book runners included Barclays, Deutsche Bank Securities, Evercore ISI, and Jefferies. Proceeds: Astera Labs itself will not receive any proceeds from the sale of shares by the existing stockholders. The underwriters have a 30-day option to purchase up to an additional 2,670,000 shares of common stock from Astera Labs at the IPO price, less underwriting discounts and commissions. Purpose and Focus: Astera Labs aims to unlock the full potential of cloud and AI infrastructure through purpose-built connectivity solutions. Astera Labs supplies its products to such companies like Nvidia, Advanced Micro Devices, Intel Corp, Amazon. The future of Astera Labs: our view: more details are provided on our site. Financial performance needs improvement Valuation Summary

Leah Houston, MD Timely topic and insightful article! Two important points for me were: -the largest barrier to physician unionization was simply lack of access and -the top priority for unionization was to alleviate burnout The data shows that we (physicians) are following the same trends as healthcare systems: mergers & acquisitions are forcing us into becoming a "managed" groups that are owned by a relatively small and powerful group of corporations. Essentially an oligopolistic market. So far, consolidation of the healthcare market has consistently failed to produce consistent and quantifiable reductions in costs and improvement in quality. Do we not think the same effect is being seen for the providers that are being affected by this consolidation in the healthcare industry? Two counter-balancing solutions: -well-regulated and purposeful unionization where appropriate -increasing representation of physicians in ALL divisions of administration and leadership

📣 Excited to share my recent interview with Nick Morton, CIO of Resonant Asset Management, where we discussed the macro drivers affecting the US economy. Nick shared his insights on the pull/push factors of Monetary policy versus Fiscal policy and highlighted some of his top stocks for 2024. One of his picks, the medtech ASX200 winner, Cochlear, caught my attention. Check out our conversation here: https://lnkd.in/g8_zkNhX #USmacrodrivers #stocks2024 #Cochlear #medtech #ResonantAssetManagement

\*\*Tempus AI Stock: Everything You Need to Know About the Upcoming IPO\*\* 🚀 Tempus AI is set to revolutionize healthcare with its upcoming IPO! Discover why this stock is a hot pick, its financial performance, market potential, and the risks involved. 📈 🔗 [Read more]\(https://lnkd.in/gUZ3-hEv) \#TempusAI \#StockMarket \#IPO \#HealthTech \#Investment